MGMT and central nervous system cancer: Our observation that 4 of 12 patients experience changes and that loss of methylation is more frequent than acquisition supports the notion that during glioma progression, frequent MGMT promoter methylation changes occur, and therefore patients' responsiveness to temozolomide potentially may also change.